Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 50K | 0 | 0 | 0 |
| Gross Profit | 1M | 44K | -125K | -243K | 0 |
| Operating Income | -7M | -5M | -5M | -6M | -467K |
| EBITDA | -7M | -11M | -15M | -5M | -87K |
| Net Income | -7M | -10M | -15M | -9M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.293
+0.00% today
1Y Change
-90.71%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Longevity Health Holdings Inc. (XAGE) is a Healthcare stock with listed on OTC. The stock last traded around $0.29 and down 90.7% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +3701.4%, EPS growth of -702.0%, a dividend yield of 0.0%. What stands out right now is revenue +3701.4%, EPS -702.0%, free cash flow +23.8% with operating margin -371.6% and ROIC 135.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XAGE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XAGE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XAGE Max Drawdown
-95.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XAGE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$6.5M
+28.4% YoY
Free Cash Flow
-$1.2M
+65.5% YoY
Revenue Growth
+3701.4%
EPS Growth
-702.0%
Gross Margin
57.2%
Net Margin
-361.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 50K | 0 | 0 | 0 |
| Gross Profit | 1M | 44K | -125K | -243K | 0 |
| Operating Income | -7M | -5M | -5M | -6M | -467K |
| EBITDA | -7M | -11M | -15M | -5M | -87K |
| Net Income | -7M | -10M | -15M | -9M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 707K | 157K | 3M | 128K | 774K |
| Total Assets | 2M | 1M | 64M | 2M | 2M |
| Total Liabilities | 8M | 6M | 39M | 40M | 31M |
| Shareholder Equity | -6M | -5M | 25M | -38M | -30M |
| Total Debt | 500K | 639K | 2M | 4M | 10M |
| Net Debt | -207K | 482K | -776K | 4M | 9M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+65.7% YoY
Capital Expenditures
7K
-1.5% YoY
Free Cash Flow
1M
+65.5% YoY
Key ratios
Gross Margin
57.2%
Operating Margin
-371.6%
Net Margin
-361.0%
ROE
158.9%
Debt / Equity
-0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.